156 related articles for article (PubMed ID: 38771501)
1. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Clin Exp Med; 2024 May; 24(1):105. PubMed ID: 38771501
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
3. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
Wada F; Jo T; Arai Y; Kitawaki T; Mizumoto C; Kanda J; Nishikori M; Yamashita K; Nagao M; Takaori-Kondo A
Sci Rep; 2022 Nov; 12(1):18696. PubMed ID: 36333521
[TBL] [Abstract][Full Text] [Related]
4. Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma.
Carniti C; Caldarelli NM; Agnelli L; Torelli T; Ljevar S; Jonnalagadda S; Zanirato G; Fardella E; Stella F; Lorenzini D; Brich S; Arienti F; Dodero A; Chiappella A; Magni M; Corradini P
Blood Adv; 2024 Apr; 8(8):1968-1980. PubMed ID: 38359407
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
7. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
8. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
10. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
13. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
14. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
15. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Choquet S; Soussain C; Azar N; Morel V; Metz C; Ursu R; Waultier-Rascalou A; di Blasi R; Houot R; Souchet L; Roos-Weil D; Uzunov M; Quoc SN; Jacque N; Boussen I; Gauthier N; Ouzegdouh M; Blonski M; Campidelli A; Ahle G; Guffroy B; Willems L; Corvilain E; Barrie M; Alcantara M; le Garff-Tavernier M; Psimaras D; Weiss N; Baron M; Bravetti C; Hoang-Xuan K; Davi F; Shor N; Alentorn A; Houillier C
Am J Hematol; 2024 Jul; 99(7):1240-1249. PubMed ID: 38586986
[TBL] [Abstract][Full Text] [Related]
16. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.
Kittai AS; Huang Y; Gordon M; Denlinger N; Mian A; Fitzgerald L; Bishop J; Nagle S; Stephens DM; Jaglowski S; Hill B; Danilov AV
Transplant Cell Ther; 2021 Jan; 27(1):46-52. PubMed ID: 33002640
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
19. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
[TBL] [Abstract][Full Text] [Related]
20. High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy.
Jin J; Lin L; Meng J; Jiang L; Zhang M; Fang Y; Liu W; Xin X; Long X; Kuang D; Ding X; Zheng M; Zhang Y; Xiao Y; Chen L
Mol Ther; 2024 May; 32(5):1252-1265. PubMed ID: 38504519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
